Zeke Capital Advisors LLC cut its holdings in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 8.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,428 shares of the medical instruments supplier’s stock after selling 1,092 shares during the period. Zeke Capital Advisors LLC’s holdings in DENTSPLY SIRONA were worth $667,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in XRAY. Hanseatic Management Services Inc. bought a new position in DENTSPLY SIRONA during the 1st quarter worth approximately $30,000. Cornerstone Advisors Inc. increased its stake in shares of DENTSPLY SIRONA by 62.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 904 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 346 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at $58,000. Private Capital Group LLC increased its stake in shares of DENTSPLY SIRONA by 74.7% in the 1st quarter. Private Capital Group LLC now owns 1,223 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 523 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its stake in shares of DENTSPLY SIRONA by 1,047.2% in the 1st quarter. Quadrant Capital Group LLC now owns 1,411 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 1,288 shares in the last quarter. Institutional investors and hedge funds own 91.86% of the company’s stock.
NASDAQ XRAY traded down $0.39 during mid-day trading on Tuesday, hitting $51.10. The company’s stock had a trading volume of 194,128 shares, compared to its average volume of 1,580,547. The firm’s 50 day moving average price is $56.76. DENTSPLY SIRONA Inc has a twelve month low of $33.93 and a twelve month high of $59.40. The company has a quick ratio of 1.39, a current ratio of 2.08 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $12.35 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 1.95 and a beta of 0.97.
The company also recently disclosed a quarterly dividend, which was paid on Friday, July 12th. Shareholders of record on Friday, June 28th were issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 0.68%. This is an increase from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. The ex-dividend date was Thursday, June 27th. DENTSPLY SIRONA’s payout ratio is currently 17.41%.
XRAY has been the subject of several research analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $55.00) on shares of DENTSPLY SIRONA in a research note on Tuesday, July 9th. BidaskClub lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Tuesday. Zacks Investment Research lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating and set a $62.00 price objective for the company. in a research note on Monday, May 27th. Wolfe Research initiated coverage on shares of DENTSPLY SIRONA in a research note on Thursday, May 30th. They issued a “peer perform” rating for the company. Finally, Wellington Shields upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $53.77.
In related news, SVP Maureen J. Macinnis sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $56.06, for a total value of $840,900.00. Following the transaction, the senior vice president now directly owns 25,360 shares of the company’s stock, valued at approximately $1,421,681.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Maureen J. Macinnis sold 54,402 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $55.00, for a total transaction of $2,992,110.00. Following the completion of the transaction, the senior vice president now directly owns 50,962 shares in the company, valued at $2,802,910. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 22,720 shares of company stock worth $1,223,243 and have sold 104,462 shares worth $5,755,004. 0.62% of the stock is owned by insiders.
DENTSPLY SIRONA Profile
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.